Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Clinical trial NCT02612311 · TERMINATED
Trial details
- NCT number
- NCT02612311
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-19
- Primary completion
- 2023-02-22
- Enrollment
- 603
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.